Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: Dummy run and individual case review

Radiotherapy and Oncology

Volumn 90, Issue 3, 2009, Pages 285-290

  Matzinger, Oscar ^a,b   Poortmans, Philip ^c   Giraud, Jean Yves ^d   Maingon, Philippe ^e   Budiharto, Tom ^a   van den Bergh, Alfons C M ^f   Davis, J Bernard ^g   Musat, Elena ^h   Ataman, Fatma ^a   Huyskens, Dominique P ⁱ   Gulyban, Akos ^a   Bolla, Michel ^d  

^a EORTC Headquarters ^*  (Belgium)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c DR BERNARD VERBEETEN INSTITUTE   (Netherlands)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e CENTRE GEORGES FRANÇOIS LECLERC   (France)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ QA team in Radiotherapy Physics   (Belgium)

Author keywords

Dummy run; Individual case review; Prostate cancer; Quality assurance; Radiotherapy; Randomized trial

Indexed keywords

ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HEALTH CARE PLANNING; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY CONTROL; RADIATION DOSE; TREATMENT PLANNING;

ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RESEARCH DESIGN;

EID: 61549092204     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.10.022     Document Type: Article

References (23)

1. Pettersen M.N., Aird E., and Olsen D.R. Quality assurance of dosimetry and the impact on sample size in randomized clinical trials. Radiother Oncol 86 (2008) 195-199
2. Bentzen S.M., Bernier J., Davis J.B., et al. Clinical impact of dosimetry quality assurance programmes assessed by radiobiological modelling of data from the thermoluminescent dosimetry study of the European Organization for Research and Treatment of Cancer. Eur J Cancer 36 (2000) 615-620
3. Poortmans P.M., Venselaar J.L., Struikmans H., et al. The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: a quality-assurance report on the dummy run of EORTC Phase III randomized trial 22922/10925 in Stage I-III breast cancer (1). Int J Radiat Oncol Biol Phys 49 (2001) 1399-1408
4. Poortmans P.M., Davis J.B., Ataman F., Bernier J., and Horiot J.C. The quality assurance programme of the Radiotherapy Group of the European Organisation for Research and Treatment of Cancer: past, present and future. Eur J Surg Oncol 31 (2005) 667-674
5. Budiharto T., Musat E., Poortmans P., et al. Profile of European radiotherapy departments contributing to the EORTC Radiation Oncology Group (ROG) in the 21st century. Radiother Oncol 88 (2008) 403-410
6. Ataman F., Poortmans P., Davis J.B., et al. High conformality radiotherapy in Europe: thirty-one centres participating in the quality assurance programme of the EORTC prostate trial 22991. Eur J Cancer 40 (2004) 2411-2416
7. Poortmans P.M., Ataman F., Davis J.B., et al. Quality assurance in the EORTC phase III randomised 'boost vs. no boost' trial for breast conserving therapy: comparison of the results of two individual case reviews performed early and late during the accrual period. Radiother Oncol 76 (2005) 278-284
8. Jeanneret-Sozzi W., Moeckli R., Valley J.F., et al. The reasons for discrepancies in target volume delineation: a SASRO study on head-and-neck and prostate cancers. Strahlenther Onkol 182 (2006) 450-457
9. Kouloulias V.E., Giraud J.Y., Davis B.J., Dusserre A., Zurlo A., and Bolla M. Quality assurance of the 22961 EORTC trial. A phase III study of the optimal combination of hormonal adjuvant treatment by LHRH analogue and radiation therapy for the management of locally advanced prostate cancer: the dummy run. Radiother Oncol 73 (2004) 11-20
10. Seddon B., Bidmead M., Wilson J., Khoo V., and Dearnaley D. Target volume definition in conformal radiotherapy for prostate cancer: quality assurance in the MRC RT-01 trial*1. Radiother Oncol 56 (2000) 73-83
11. Liu Y.M., Ling S., Langen K.M., et al. Prostate movement during simulation resulting from retrograde urethrogram compared with "natural" prostate movement. Int J Radiat Oncol Biol Phys 60 (2004) 470-475
12. Debois M., Oyen R., Maes F., et al. The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer. Int J Radiat Oncol Biol Phys 45 (1999) 857-865
13. Boehmer D., Maingon P., Poortmans P., et al. Guidelines for primary radiotherapy of patients with prostate cancer. Radiother Oncol 79 (2006) 259-269
14. Carroll P.R., Coakley F.V., and Kurhanewicz J. Magnetic resonance imaging and spectroscopy of prostate cancer. Rev Urol 8 Suppl 1 (2006) S4-S10
15. Parker C.C., Damyanovich A., Haycocks T., Haider M., Bayley A., and Catton C.N. Magnetic resonance imaging in the radiation treatment planning of localized prostate cancer using intra-prostatic fiducial markers for computed tomography co-registration. Radiother Oncol 66 (2003) 217-224
16. Villeirs G.M., Van Vaerenbergh K., Vakaet L., et al. Interobserver delineation variation using CT versus combined CT + MRI in intensity-modulated radiotherapy for prostate cancer. Strahlenther Onkol 181 (2005) 424-430
17. van der Laan H.P., van den Bergh A., Schilstra C., Vlasman R., Meertens H., and Langendijk J.A. Grading-system-dependent volume effects for late radiation-induced rectal toxicity after curative radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 1138-1145
18. Storey M.R., Pollack A., Zagars G., Smith L., Antolak J., and Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48 (2000) 635-642
19. Jackson A., Skwarchuk M.W., Zelefsky M.J., et al. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 49 (2001) 685-698
20. Vargas C., Yan D., Kestin L.L., et al. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: Use of dose-volume constraints to achieve rectal isotoxicity. Int J Radiat Oncol Biol Phys 63 (2005) 141-149
21. Peeters S.T., Lebesque J.V., Heemsbergen W.D., et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 64 (2006) 1151-1161
22. Chan L.W., Xia P., Gottschalk A.R., et al. Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 72 (2008) 69-77
23. Poortmans P., Bossi A., Vandeputte K., et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol 84 (2007) 121-127